We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
5.00 | 5.25 | 5.125 | 5.125 | 5.125 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -12.19 | 27.31M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
09:15:39 | O | 1,656 | 5.125 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
31/1/2024 | 07:00 | UK RNS | Eden Research plc Board Change |
22/1/2024 | 11:42 | ALNC | Eden Research annual revenue to beat market consensus amid sales boost |
22/1/2024 | 07:00 | UKREG | Eden Research plc Trading Update |
19/1/2024 | 15:00 | UKREG | Eden Research plc Holding(s) in Company |
09/1/2024 | 11:29 | ALNC | Eden Research's Mevalone gains regulatory approval in California |
09/1/2024 | 07:01 | UKREG | Eden Research plc Mevalone Approval in the State of California |
18/12/2023 | 11:48 | ALNC | Eden Research shares jump as Ecovelex gets approved in Italy |
18/12/2023 | 07:00 | UKREG | Eden Research plc Ecovelex(TM)2023 Approval in Italy |
28/11/2023 | 07:00 | RNSNON | Eden Research plc Small Cap Virtual Investor Conference |
01/11/2023 | 07:00 | UKREG | Eden Research plc Change of Nominated Adviser and Broker |
Eden Research (EDEN) Share Charts1 Year Eden Research Chart |
|
1 Month Eden Research Chart |
Intraday Eden Research Chart |
Date | Time | Title | Posts |
---|---|---|---|
18/3/2024 | 22:21 | Eden Research | 17,153 |
08/2/2024 | 07:42 | Eden....Onward and Upwards! | 52 |
21/6/2023 | 11:05 | The sterile garden of Eden | 123 |
29/3/2022 | 15:04 | Eden Research | 14 |
29/3/2022 | 13:36 | Eden Research - Who Is Behind Thallo Eco Products Corp? | 27 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
09:15:40 | 5.13 | 1,656 | 84.87 | O |
Top Posts |
---|
Posted at 19/3/2024 08:20 by Eden Research Daily Update Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 5.13p.Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £27,307,649. Eden Research has a price to earnings ratio (PE ratio) of -12.19. This morning EDEN shares opened at 5.13p |
Posted at 08/3/2024 06:22 by supersonico With the Insecticide I use the ITC2 Corteva model.Eden are inside the big tent where different rules apply for the new #Make-Biologicals-Gr The insecticide falls into the inthecoming2 big tent model where imo the GOA have been working with Eden since the #Celebrated Women of Syngenta ... Camilla Corsi and Smith shared a platform five years ago. The terms and agreements between 'multiple interested parties' might well be more complicated but the progress has been steady and there has been plenty of time to talk terms since ITC1 evolved into the #collaboration ITC2 epoch. AWAGATWT. Annual Eden Insecticide / development update...2019- Jan 2024 15 January 2019; The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. Whilst it is early in the development of these formulations, initial results have been encouraging. 14 January 2020 Looking forward, we expect to be able to announce further marketing authorisations for both Mevalone and Cedroz as well as progress that is being made with existing and new partners in areas such as seed treatments, insecticides and other applications where the use of our active ingredients and Sustaineä encapsulation technology can bring important benefits to our commercial partners, growers, and ultimately consumers who benefit from sustainable agriculture." 11 February 2021 Development work continued largely as hoped during 2020, including on Eden's insecticide and seed treatment products. In addition, the Company continues to work with a number of parties to develop products that avoid polymer encapsulation using Eden's proprietary Sustaine® technology with third party active ingredients. 2nd March 2022 Development of Eden's seed treatment and insecticide products continues on track with good progress made in 2021 and the Corteva partnership has moved into the next stage of development triggering a milestone payment to Eden. 10 January 2023 Field trials in 2021 and 2022 have produced encouraging results for our insecticide candidates. The Company is pleased to be in position where it has now agreed on a final formulation, entered into testing agreements and sent trial-scale samples to multiple interested parties who are undertaking their own trial work. Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results. The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US. 22 January 2024 A number of potential commercial partners for Eden's insecticide product ran, between them, a large number of field trials in 2023 and, so far, these have produced encouraging results. Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results. The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US. Eden has now started commercial discussions with various potential partners to begin the evaluation of who to appoint as distribution partner for the insecticide product and shall update the market during 2024, as appropriate. .................... |
Posted at 02/3/2024 11:19 by investingisatrickygame Timbo_Slice12p would give Eden a market cap of £64 million Cavendish currently has a target price of 20p, so £107 million market cap Eden talks about operating in $billion markets with Compound Annual Growth Rates of 15%+ It is not unreasonable for an investor to presume that Eden's target market cap is much higher than £107 million. That Cavendish number takes no account of the impending insecticide deal or its label extension (see Placing RNS) or the label extension(s) to Ecovelex or Powdery Mildew label extensions applied for on Mevalone, but not yet received e.g. France. I believe Eden considers itself to be at the forefront or a leader in some of the work it is doing. That could be supported by, for example, Ecovelex and Corteva's recognition of the same. Furthermore, Eden self-declares that it is "Our vision is to be a global leader in sustainable crop protection through the development of bioactive products enabled or enhanced by our novel encapsulation and delivery technologies." You cannot make such statements and operate in $billion markets and be pleased with a £107 million market cap. That makes no sense on any level for a company in the process of 'global expansion'. Given the above, Eden needs to sell this vision more directly to investors to mobilise the share price and get belief into the Company, visible in its share price, so that investors truly believe in the Company, their investment and that the value of their £1 today is near guaranteed to be worth significantly more in the near future. If not, we need to talk about being a participant in £million markets and reset both ambition and expectation. I'm pretty sure the former statement sits better and more accurately, so Eden needs to communicate this more effectively so it it properly understood and so that such commentary and written words are not throw away, meaningless statements. |
Posted at 24/2/2024 16:01 by investingisatrickygame Information PostCavendish price target 20p Eden share price below 6p Upside 300%+++ As KittyBiscuits say's, just an information post :) |
Posted at 14/2/2024 09:01 by investingisatrickygame Hi Super,if you are referring to the podcast US conference, not really. Like AttyG, who can speak for themself, and comment here again if they wish too, I think Eden is likely understating numbers. I will give 2 examples 1) In the US Podcast & slide presentation Alex Abrey sited the Ecovelex opportunity as €35-40 million globally. However, in the 2020 Placing, Subscription and Open Offer RNS, Eden states the Ecovelex opportunity as €40 million from 'European geographies alone. At that point in time it was referred to 'this product' and not named as Ecovelex. 2) In the same presentation, they say the insecticide opportunity has the same €35-40 million opportunity globally. However, on Eden's website they state that the insecticide has a 5%-10% opportunity of an €850 million market from the US and Europe alone Source: So for me, the numbers and the geographies don't align. Even allowing for addressable markets changing, their is a huge different from 'European geographies alone' and globally. Similarly with the insecticide. It only serves to confuse understanding of what the opportunity is. So questions What is the European Ecovelex maize opportunity? What is the US Ecovelex maize opportunity? What is the ROW Ecovelex maize opportunity? Then to suggest what might be as Corteva has put it in the public domain What is the European Ecovelex Sunflower opportunity that Corteva is evaluating? Similarly with the US and the ROW. It is a case of setting the scene of what might be. No one is going to get excited about. 2023 AGM Presentation When you look at the numbers on slides 3 & 5 and then look at 'current' € value prospects by product, they are totally disconnected. For me at least, they are. Might it be better with Mevalone, for instance, to say that the addressable market for fungicides treating grapes (Eden's current primary target for Mevalone) is X and then show Eden's target sales against this. Isn't this a more realistic measure of what Eden is seeking to achieve. The global biopesticide market may be worth $11 billion by 2027 growing at 15% CAGR as detailed on slide 5, but that has no real world correlation to Eden, their prospects and investor expectations. Eden for a while has been talking global market $billions, but that is not the world we are in. We recently did a video interview entitled 'global expansion', but we didn't, in my view, excite investors about what that global expansion looks like and why you should invest in Eden. No NDA is going to restrict that story being told. When you IPO, you tell investors why they should place their money in your company. Well for me, that is an ongoing journey of telling investors why they should invest in your company. It doesn't stop post listing. I think there is a lot for Eden to review about how they woo investors in order to realise the share price they and we believe we deserve. |
Posted at 14/2/2024 07:01 by investingisatrickygame "Only sales/profits will bring the share price up"I'd have to respectfully disagree. Many a loss making company has seen a dramatic and sustained rise in their share price because the company has talked about the forward prospects and the market has been excited by those prospects. Inevitably they can trade on ridiculous, to you and me, P/E ratios, but they do so because the market is excited by their prospects and believes in them. The market then invests their hard earned $/£/€ and the share price reacts in a positive way. Ultimately, they do have to achieve what they say, but saying it in a certain way does allow the share price to move upwards. This is usually true of companies with global opportunities and Eden has global opportunities. It matters not whether they operate in a regulated market or not. Super, Many companies will be bound by NDA's for all kinds of things. Eden is not unique in this position and it doesn't prevent them talking Eden's prospects up where it is justified. I for one, simply don't believe we have gone to the effort of regulatory approvals post years of trials in what is currently 19 countries for the market to believe that footprint is worth just £30 million. That is a ridiculous valuation for addressing global agricultural problems and when Eden references $billion+ markets with the biopesticide market experiencing 15%+ CAGR. I choose to believe that Eden's know-how around what they do with terpenes is worth more than £30 million alone. To quote our chairman " I am used to seeing one molecule do one thing in my career, but with Eden, one molecule can do many things". Member of the Board of Management of Bayer Cropscience Head of Bayer Cropscience Bioscience division You don't hold such (relevant to Eden) career positions, make a statement such as that and based on such long-term insight and believe your company is worth just £30 million. The share price is completely and utterly disconnected from where it should be and the company needs to do something about it. Cavendish needs to help them too. Hawthorn needs to try harder. |
Posted at 12/2/2024 21:06 by investingisatrickygame Eden has done a series of PR/IR exercises for a US audience now and it would appear to me, no takers thus far. I haven't seen a volume change to suggest so. That said, the pragmatic amongst us accept that it takes time. Even so, allowing for those events, there has been enough time for some to come into the market and buy stock.The share price sits at 5.625p showing a MCap of circa £30 million which would be even less, but for the recent increase in the number of shares in issue following a capital raise. 'Our' share price has made NO progress in the last 5+ years, yet the Company has increased regulatory approvals, label extensions & NPD such as Ecovelex. There is one known major announcement left to come and it is our insecticide. Treating 4 insects as opposed to the standard 2, we wait to see if we will deal with one global partner or several partners. After this announcement, there is no known new products to be announced and the known future is regulatory approvals, as and when and label extensions, as and when. Even if there are new products, they will be and revenue will be a minimum 3 years away which Eden has stated itself. So if the insecticide announcement doesn't substantially move our share price, what will and when? To me, the insecticide is a pivotal moment. If Eden doesn't grab the attention of the investment community with that announcement and the share price doesn't factor in future income and possibilities then to me, others may well disagree, Eden looks vulnerable. Others with deeper pockets may well see that those pockets are better able to more quickly deliver revenue in a sustainable way that perhaps, Eden cannot. For all of Eden's ingenuity and know how, as a public company, they have to satisfy the investment community & shareholders and a continued inability to do that, as evidenced by the share price, can surely only lead to one outcome. We can't talk about global expansion, 19 countries, some products that have been available for years, but with revenue subject to weather (an unknown every year and difficult if not impossible to financially forecast) and at the same time talk about $billion markets without penetration in any meaningful way. Either we have the capability now to sell tens of $millions of product as AttyG has suggested, or we don't. If we do, then the investment proposition has to be sold more appropriately, more aggressively, such that it is sufficiently realised to create investment momentum, something I am not sure I have ever seen in Eden. |
Posted at 24/1/2024 17:42 by supersonico Annual Eden Insecticide / development update...2019- Jan 202415 January 2019; The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. Whilst it is early in the development of these formulations, initial results have been encouraging. 14 January 2020 Looking forward, we expect to be able to announce further marketing authorisations for both Mevalone and Cedroz as well as progress that is being made with existing and new partners in areas such as seed treatments, insecticides and other applications where the use of our active ingredients and Sustaineä encapsulation technology can bring important benefits to our commercial partners, growers, and ultimately consumers who benefit from sustainable agriculture." 11 February 2021 Development work continued largely as hoped during 2020, including on Eden's insecticide and seed treatment products. In addition, the Company continues to work with a number of parties to develop products that avoid polymer encapsulation using Eden's proprietary Sustaine® technology with third party active ingredients. 2nd March 2022 Development of Eden's seed treatment and insecticide products continues on track with good progress made in 2021 and the Corteva partnership has moved into the next stage of development triggering a milestone payment to Eden. 10 January 2023 Field trials in 2021 and 2022 have produced encouraging results for our insecticide candidates. The Company is pleased to be in position where it has now agreed on a final formulation, entered into testing agreements and sent trial-scale samples to multiple interested parties who are undertaking their own trial work. Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results. The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US. 22 January 2024 A number of potential commercial partners for Eden's insecticide product ran, between them, a large number of field trials in 2023 and, so far, these have produced encouraging results. Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results. The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US. Eden has now started commercial discussions with various potential partners to begin the evaluation of who to appoint as distribution partner for the insecticide product and shall update the market during 2024, as appropriate. .................... 30 November 2023 Abrey commentary from ..Presentation from the November 30 Small Cap Growth Virtual Investor Conference "We have undertaken a large number of field trials ourselves, this year we had Partners ..potential partners undertaking their own trials in excess of 140 in total spread across the potential partners so we hope and expect by the end of this year to have all the results from those various trials that have been undertaken and early indications are positive. We will then move into commercial negotiations with those potential partners ..we would look to do distribution agreements with some or maybe one or all of those potential partners and it could be it's a global deal or a regional or even country by country ..it remains to be seen and depends on the business cases put forward to us ..but this one we're really excited about ..it's a big opportunity ..there is a dearth of Bio-insecticides available which is why we have seen so much interest for this product ..in terms of the actual opportunity again this is a big one for us potentially around $35-$40m per annum at peak". (Eden Research plc (OTCQB: EDNSF | AIM: EDEN): Virtual Investor Conferences / |
Posted at 23/1/2024 08:02 by investingisatrickygame Super,yes, it was the ShareSoc event. So two events we know of. Hopefully Eden will now reframe their messaging and add reasons to invest in Eden, such that investors choose to place their $'s and £'s in Eden rather than elsewhere. Certainly, there are enough triggers to now do so with one remaining major announcement that we have been primed for, that being the insecticide and thereafter, it should be easy for investors to understand that the primary activities to expect will be label extensions and new regulatory submissions and permissions. To support that end aim, a nice data table, effectively an update of the Appendix in this RNS from 2020, would be useful, but adding 2 additional columns. Alongside 'estimated market side' (addressable market) add a column that shows anticipated market share and one further column that shows the remaining period of regulatory approval. Historically, Eden has already shown market share anticipated on their website for one product and the regulatory approval period would be very helpful to see in one central place for all territories, by product, as it will already be in the public domain anyway. This will allow investors to calculate total potential continuous income in the eyes of the Company and therefore start to understand the potential value and future value of the Company. It is only a steer and not exact, but a guide is better than flying blind and will support decisions to further invest or/and invest for the first time. 'Build it and they will come' might be an apt phrase with our insecticide and the 10 or 11 partners that have evaluated it, but it also applies to Eden's shareholders. Build the investment story and they will come. That's what we need to do, don't we, to help get the share price up to where it should be. Here's another one for those old enough. 'I liked the shaver so much, I bought the company'. The way Eden is building, someone too might like Eden very much. That's why the share price needs to represent proper value at all times. |
Posted at 22/1/2024 06:38 by supersonico NUMBER OF AIM SECURITIES IN ISSUEAs of 3 January 2024, the number of shares in issue was 533,352,523. SIGNIFICANT SHAREHOLDERS As of 3 January 2024 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 53,364,313 10.01% Gresham House Asset Management Limited 52,882,786 9.92% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Interactive Investor 33,363,457 6.26% Canaccord Genuity Wealth Management 30,276,307 5.68% Unicorn Asset Management 23,076,923 4.33% Rathbones 23,040,287 4.32% Atul Unadkat 22,099,924 4.14% JM Finn Nominees Limited 20,147,562 3.78% Amati Global Investors 16,744,070 3.14% BGF Investment Management Limited 16,000,576 3.00% .................... As of 20 July 2023, the number of shares in issue was 381,108,607. SIGNIFICANT SHAREHOLDERS As of 20 July 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 45,307,219 11.89% Sipcam Oxon S.p.A. 37,614,830 9.87% Interactive Investor 31,957,945 8.39% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% BGF Investment Management Limited 20,233,000 5.31% JM Finn Nominees Limited 19,635,562 5.15% Atul Unadkat 18,811,765 4.94% Rathbone Nominees Limited 13,661,661 3.58% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% HSDL Stockbrokers 12,436,733 3.26% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% ................... NUMBER OF AIM SECURITIES IN ISSUE As of 21 March 2023, the number of shares in issue was 380,858,607. SIGNIFICANT SHAREHOLDERS As of 21 March 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 51,733,000 13.58% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 31,737,596 8.33% Gresham House Asset Management Limited 27,845,445 7.31% Interactive Investor 25,172,555 6.61% Canaccord Genuity Group Inc 22,584,000 5.93% JM Finn Nominees Limited 19,839,762 5.21% Atul Unadkat 18,117,567 4.76% Rathbone Nominees Limited 15,621,872 4.10% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% SHARES NOT IN PUBLIC HANDS In the terms of AIM Rules published July 2016 and insofar as it is aware, at 21 March 2023, 31.71% of the Company's AIM securities was not in public hands. .................... Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 03 Dec 2022 - 07:03:11 - 13502 of 14935 Eden Research - EDEN Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 05 Oct 2022 - 08:52:18 - 13219 of 14935 Eden Research - EDEN Selling yes..but it's a dribble which has been bought by Atul etal. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% 1 |
Posted at 11/1/2024 09:37 by monet Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7, |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |